Illumina Dropped List Prices, Cut Discounts for Infinium Kits After Affy Slashed 500K Price | GenomeWeb
NEW YORK (GenomeWeb News) — Illumina CEO Jay Flatley said the company in September dropped the list prices and reduced the discounts for its Infinium whole-genome genotyping kits a few weeks after rival Affymetrix cut the price of its 500K array kit.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.